Journal article

First-line oxygen therapy with high-flow in bronchiolitis is not cost saving for the health service

Vijay S Gc, Donna Franklin, Jennifer A Whitty, Stuart R Dalziel, Franz E Babl, Luregn J Schlapbach, John F Fraser, Simon Craig, Jocelyn Neutze, Ed Oakley, Andreas Schibler

Archives of Disease in Childhood | BMJ PUBLISHING GROUP | Published : 2020


BACKGROUND: Bronchiolitis is the most common reason for hospital admission in infants. High-flow oxygen therapy has emerged as a new treatment; however, the cost-effectiveness of using it as first-line therapy is unknown. OBJECTIVE: To compare the cost of providing high-flow therapy as a first-line therapy compared with rescue therapy after failure of standard oxygen in the management of bronchiolitis. METHODS: A within-trial economic evaluation from the health service perspective using data from a multicentre randomised controlled trial for hypoxic infants (≤12 months) admitted to hospital with bronchiolitis in Australia and New Zealand. Intervention costs, length of hospital and intensive ..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC), Canberra, Australia

Awarded by National Health and Medical Research Council Centre of Research Excellence grant

Funding Acknowledgements

This work was supported by a project grant (GNT1081736) from the National Health and Medical Research Council (NHMRC), Canberra, Australia, and Queensland Emergency Medical Research Fund (QEMRF), Brisbane, Australia. Regional site funding was obtained for Ipswich Hospital from the Ipswich Hospital Foundation and the Gold Coast University Hospital (GCUH) from the GCUH Foundation. The Townsville Hospital was part funded by a SERTA grant (Study, Education and Research Trust Account). JFF and AS received a research fellowship from the Queensland Health Department, Australia. PREDICT sites were supported by a National Health and Medical Research Council Centre of Research Excellence grant for paediatric emergency medicine (GNT1058560). Victorian sites received infrastructure support from the Victorian Government's Infrastructure Support Program, Melbourne, Australia. FEB was part funded by a Royal Children's Hospital Foundation grant, a Melbourne Campus Clinician Scientist Fellowship, Melbourne, Australia and an NHMRC Practitioner Fellowship. SD was part funded by a grant from the Health Research Council of New Zealand (HRC) and Cure Kids New Zealand, Auckland, New Zealand. The high--flow equipment and consumables for all study sites were provided free of charge by Fisher & Paykel Healthcare (Auckland, New Zealand), who had no involvement in the design, conduct and analysis of the study.